Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation

Purpose. The aim of this study was to determine if the preoperative maximum standardized uptake value (SUVmax) measured by 18F-FDG PET/CT in the primary tumor has prognostic value in the group of patients with endometrial cancer.Patients, Materials, and Methods. A total of one hundred one consecutive endometrial cancer patients, age range 40–82 years (mean 62 years) and FIGO I–IV stage, who underwent 18-FDG-PET/CT within two weeks prior radical surgery, were enrolled to the study. The maximum SUV was measured and compared with the clinicopathologic features of surgical specimens. The relationship between SUVmax and overall survival was analyzed.Results. The mean preoperative SUVmax was 14.34; range (3.90–33.80) and was significantly lower for FIGO I than for higher stages (P=0.0012), as well as for grade 1 than for grade 2 and 3 (P=0.018), deep myometrial invasion (P=0.0016) and for high risk group (P=0.0004). The analysis of survival ROC curve revealed SUVmax cut-off value of 17.7 to predict high risk of recurrence. Endometrial cancer patients with SUVmax higher than 17.7 characterized by lower overall survival.Conclusion. The preoperative SUVmax measured by 18F-FDG PET/CT is considered as an important indicator reflecting tumor aggressiveness which may predict poor prognosis. High value of SUVmax would be useful for making noninvasive diagnoses and deciding the appropriate therapeutic strategy for patients with endometrial cancer.

Download Full-text

18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making

PLoS ONE ◽

10.1371/journal.pone.0133690 ◽

2015 ◽

Vol 10 (11) ◽

pp. e0133690 ◽

Cited By ~ 12

Author(s):

Maarten C. J. Anderegg ◽

Elisabeth J. de Groof ◽

Suzanne S. Gisbertz ◽

Roel J. Bennink ◽

Sjoerd M. Lagarde ◽

...

Keyword(s):

Decision Making ◽

Esophageal Cancer ◽

Cancer Patients ◽

Fdg Pet ◽

Neoadjuvant Chemoradiotherapy ◽

Surgical Decision ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct ◽

Surgical Decision Making

Download Full-text

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients

Molecular Imaging and Radionuclide Therapy ◽

10.4274/mirt.07379 ◽

2014 ◽

Vol 23 (1) ◽

pp. 12-15 ◽

Cited By ~ 7

Author(s):

Çiğdem Soydal ◽

Cabir Büte Yüksel ◽

Özlem N. Küçük ◽

İlker Ökten ◽

Elgin Özkan ◽

...

Keyword(s):

Esophageal Cancer ◽

Cancer Patients ◽

Fdg Pet ◽

Prognostic Value ◽

Tumor Volume ◽

Metabolic Tumor Volume ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

Influence of Biological Parameters Assessed in [18F]FDG PET/CT on Overall Survival in Cervical Cancer Patients

Clinical Nuclear Medicine ◽

10.1097/rlu.0000000000002733 ◽

2019 ◽

Vol 44 (11) ◽

pp. 860-863 ◽

Cited By ~ 3

Author(s):

Paulina Cegla ◽

Ewa Burchardt ◽

Andrzej Roszak ◽

Rafal Czepczynski ◽

Anna Kubiak ◽

...

Keyword(s):

Cervical Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Fdg Pet ◽

Biological Parameters ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

[18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy

Radiation Oncology ◽

10.1186/s13014-016-0614-x ◽

2016 ◽

Vol 11 (1) ◽

Cited By ~ 24

Author(s):

Fernanda G. Herrera ◽

Thomas Breuneval ◽

John O. Prior ◽

Jean Bourhis ◽

Mahmut Ozsahin

Keyword(s):

Cervical Cancer ◽

Prognostic Factors ◽

Cancer Patients ◽

Fdg Pet ◽

Metabolic Parameters ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study

Cancers ◽

10.3390/cancers11050700 ◽

2019 ◽

Vol 11 (5) ◽

pp. 700 ◽

Cited By ~ 5

Author(s):

Fabio Zattoni ◽

Elena Incerti ◽

Fabrizio Dal Moro ◽

Marco Moschini ◽

Paolo Castellucci ◽

...

Keyword(s):

Overall Survival ◽

Urothelial Carcinoma ◽

Fdg Pet ◽

Patient Management ◽

Survival Prediction ◽

Primary Tumor Site ◽

Kaplan Meier ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Objectives: To evaluate the ability of 18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40%) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74% (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4%) had recurrence/progression of disease. Moreover, 131 subjects (45.6%) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings.

Download Full-text

18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy

Technology in Cancer Research & Treatment ◽

10.1177/15330338211024655 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110246

Author(s):

Seokmo Lee ◽

Yunseon Choi ◽

Geumju Park ◽

Sunmi Jo ◽

Sun Seong Lee ◽

...

Keyword(s):

Esophageal Cancer ◽

Cancer Patients ◽

Fdg Pet ◽

Concurrent Chemoradiotherapy ◽

Curative Intent ◽

Squamous Cell Esophageal Cancer ◽

Pet Ct ◽

Significant Difference ◽

Fdg Pet Ct

Background and Aims: This study evaluated the prognostic value of 18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (18F-FDG PET/CT) performed before and after concurrent chemoradiotherapy (CCRT) in esophageal cancer. Methods: We analyzed the prognosis of 50 non-metastatic squamous cell esophageal cancer (T1-4N0-2) patients who underwent CCRT with curative intent at Inje University Busan Paik Hospital and Haeundae Paik Hospital from 2009 to 2019. Median total radiation dose was 54 Gy (range 34-66 Gy). Our aim was to investigate the relationship between PET/CT values and prognosis. The primary end point was progression-free survival (PFS). Results: The median follow-up period was 9.9 months (range 1.7-85.7). Median baseline maximum standard uptake value (SUVmax) was 14.2 (range 3.2-27.7). After treatment, 29 patients (58%) showed disease progression. The 3-year PFS and overall survival (OS) were 24.2% and 54.5%, respectively. PFS was significantly lower ( P = 0.015) when SUVmax of initial PET/CT exceeded 10 (n = 22). However, OS did not reach a significant difference based on maximum SUV ( P = 0.282). Small metabolic tumor volume (≤14.1) was related with good PFS ( P = 0.002) and OS ( P = 0.001). Small total lesion of glycolysis (≤107.3) also had a significant good prognostic effect on PFS ( P = 0.009) and OS ( P = 0.025). In a subgroup analysis of 18 patients with follow-up PET/CT, the patients with SUV max ≤3.5 in follow-up PET/CT showed longer PFS ( P = 0.028) than those with a maximum SUV >3.5. Conclusion: Maximum SUV of PET/CT is useful in predicting prognosis of esophageal cancer patients treated with CCRT. Efforts to find more effective treatments for patients at high risk of progression are still warranted.

Download Full-text

Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer

Radiology: Imaging Cancer ◽

10.1148/rycan.2020200022 ◽

2021 ◽

Vol 3 (1) ◽

pp. e200022

Author(s):

Akilan Gopal ◽

Yin Xi ◽

Rathan M. Subramaniam ◽

Daniella F. Pinho

Keyword(s):

Esophageal Cancer ◽

Fdg Pet ◽

Prognosis Prediction ◽

Pet Ct ◽

18F Fdg ◽

Metabolic Heterogeneity ◽

Fdg Pet Ct

Download Full-text

Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE

Life ◽

10.3390/life11030198 ◽

2021 ◽

Vol 11 (3) ◽

pp. 198

Author(s):

Margarida Rodrigues ◽

Kevin-Klaus Winkler ◽

Hanna Svirydenka ◽

Bernhard Nilica ◽

Christian Uprimny ◽

...

Keyword(s):

Overall Survival ◽

Fdg Pet ◽

Median Overall Survival ◽

Peptide Receptor Radionuclide Therapy ◽

Term Survival ◽

Peptide Receptor ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Peptide receptor radionuclide therapy (PRRT) has been recognized as a promising therapy against neuroendocrine tumors (NETs). The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in NETs has been a matter of controversy. The purpose of this study was to evaluate the long-term survival and efficacy of a second PRRT course with 177Lu-DOTATE in patients with advanced gastroenteropancreatic (GEP) NETs. Furthermore, the value of 18F-FDG PET/CT in these patients was evaluated. 40 patients with GEP NETs who underwent two PRRT courses with 177Lu-DOTATATE and combined examinations with 68Ga-DOTA-TOC and 18F-FDG PET/CT were evaluated. After the second PRRT course, two patients (5.0%) were in partial remission, 21 patients (52.5%) in stable disease and 17 patients (42.5%) had progressive disease. The median overall survival was 122.10 months. After the second PRRT course, the median overall survival was significantly higher (p = 0.033) in the 18F-FDG-negative group compared to the 18F-FDG-positive group (145.50 versus 95.06 months, respectively). The median time to progression was 19.37 months. In conclusion, a second PRRT course with 177Lu-DOTATE is an effective treatment approach for GEP NET patients with disease progression. A change in 18F-FDG status after PRRT may predict the disease course and survival. Patients who are 18F-FDG-negative have a significantly longer overall survival than those who are 18F-FDG-positive.

Download Full-text